Additionally, since GPC3 is over-expressed in over 50% of HCC patients (regardless of viral etiology), it is a potentially useful diagnostic imaging marker that can complement the traditionally used AFP blood biomarker. This evidence concerns the gene GPC3 and hepatocellular carcinoma.